The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are used to treat patients with non‐small cell lung cancer (NSCLC) and EGFR driver mutations. Although some patients discontinued these treatments because of adverse events, it is unclear whether switching EGFR‐TKI b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakata, Yoshihiko, Kawamura, Kodai, Shingu, Naoki, Hiroshige, Shigeo, Yasuda, Yuko, Eguchi, Yoshitomo, Anan, Keisuke, Hisanaga, Junpei, Nitawaki, Tatsuya, Nakano, Aiko, Ichikado, Kazuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379949/
https://www.ncbi.nlm.nih.gov/pubmed/30506897
http://dx.doi.org/10.1111/ajco.13103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379949/
https://www.ncbi.nlm.nih.gov/pubmed/30506897
http://dx.doi.org/10.1111/ajco.13103

Ejemplares similares